GT Biopharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Brisbane, california, march 26, 2024 (globe newswire) -- gt biopharma, inc. (the “company”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced fourth quarter and full-year 2023 results for the period ended december 31, 2023.

Brisbane, california, feb. 01, 2024 (globe newswire) -- gt biopharma, inc. (nasdaq: gtbp) (the “company”), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, announced today that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30. the reverse stock split will become effective at 5:00 p.m. eastern time, on february 2, 2024. the company's common stock will continue to be traded on the nasdaq capital market under the symbol “gtbp” and will begin trading on a post-split basis at the market open on february 5, 2024. the cusip number for the common stock following the reverse stock split will be 36254l 308...

Brisbane, california, dec. 06, 2023 (globe newswire) -- gt biopharma, inc. (nasdaq: gtbp) (the “company”), announced that the two leading independent proxy advisory firms, institutional shareholder services inc. (“iss”) and glass lewis & co. (“glass lewis”), have recommended gt biopharma stockholders entitled to vote at the company's 2023 special meeting of stockholders (the “special meeting”) to vote “ for ” proposal items number 1 and 2. if approved, proposal no. 1. will provide the company's board of directors (the “board”) with the option to implement a reverse stock split of the company's issued and outstanding common stock (the “reverse split”), if deemed necessary in the future, to maintain the company's listing on the nasdaq capital market (“nasdaq”).

Brisbane, california, dec. 04, 2023 (globe newswire) -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced the submission of an investigational new drug (ind) application with the us food and drug administration (fda) for the development of gtb-3650, a 2nd generation nanobody trike® for the treatment of patients with cd33+ leukemia, including relapsed/refractory acute myelogenous leukemia (aml) and high-risk myelodysplastic syndrome (mds).

Brisbane, california, nov. 06, 2023 (globe newswire) -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced positive preclinical data in highlighting gtb-5550's potential in prostate cancer. martin felices, phd, associate professor of medicine at the university of minnesota, presented these data on saturday, november 4th at the society for immunotherapy of cancer (sitc) annual meeting 2023, which is being held in san diego, california november 1-5.

GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

GT Biopharma, Inc. (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Dr. Jeffrey Miller, MD, GT Bipharma's Consulting Chief Medical Officer and Chief Scientific Officer, will present a corporate overview at H.C. Wainwright's Cell Therapy Virtual Conference taking place on February 28, 2023. Company management will also be participating in 1x1 meetings during the event.

BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that management will present in-person at H.C. Wainwright's 24th Annual Global Investment Conference taking place September 12-14, 2022 at the Lotte New York Palace. Company management will also be participating in 1x1 meetings during the event.

BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced that management will present at H.C. Wainwright's Hybrid Global Investment Conference. The conference will take place May 23-26, 2022 at the Fontainebleau, Miami Beach Hotel, Miami Beach, Florida.

BRISBANE, Calif., Feb. 24, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that GT Biopharma will be participating in the following upcoming medical conferences: Abstract and poster presentation details are as follows: ESMO Targeted Anticancer Therapies Congress (TAT) (March 7-8, 2022) Title: Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using Tri-specific Killer Engager (TriKE)  Abstract Number:   250 Session:    Immunotherapy Presentation Type:  Poster Session Date and Time:  March 7, 9:20AM (CET) (On-demand e-poster display)   Location:          Virtual Poster Board Number:   17P 48th Annual European Society for Blood and Marrow Transplantation (EBMT) (March 19-23, 2022) Title:                  A Tri-specific Killer Engager (TriKE) against B7-H3 enhances NK cell mediated killing of multiple myeloma Abstract Number:        AS-EBMT-2022-00508 Session:                       New Drugs- and Cell-Based Immune Therapies Presentation Type:      Poster Session Date and Time:  March 19, 2022, 9:50 AM (CET) Location:                        Prague Congress Center, Czech Republic Poster Board Number:  P153 American Association for Cancer Research (AACR) Annual Meeting (April 8-13, 2022) Title: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas Abstract Number: Abstract control number 3334, permanent abstract number 3435 Session: Clinical Research Excluding Trials, Combination Immunotherapies / Therapeutic Antibodies Presentation Type: Poster Session Date and Time: April 12, 2022 1:30 PM – 5:00 PM Location: Ernest N.

BRISBANE, Calif., Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® protein biologic technology platform, announced today that Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO will be participating in a Fireside Chat at the upcoming B.

GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness

BEVERLY HILLS, Calif., Sept. 20, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE platform, today announced Dr. Jeffrey Miller's mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021.

OXIS International Inc. (GTBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).